Abstract
Deferasirox is an FDA-approved iron chelator used in the treatment of iron toxicity. In this work, we report the use of several deferasirox derivatives as lanthanide chelators. Solid-state structural studies of three representative trivalent lanthanide cations, La­(III), Eu­(III), and Lu­(III), revealed the formation of 2:2 complexes in the solid state. A 1:1 stoichiometry dominates in DMSO solution, with Ka values of 472 ± 14, 477 ± 11, and 496 ± 15 M–1 being obtained in the case of these three cations, respectively. Under the conditions of competitive precipitation in the presence of triethylamine, high selectivity (up to 80%) for lutetium­(III) was observed in competition with La­(III), Ce­(III), and Eu­(III). Theoretical calculations provided support for the observed selective crystallization.
Funding Information
  • Welch Foundation (F-0018)
  • Los Alamos National Laboratory (LA-UR-22-32546)
  • Basic Energy Sciences (2020LANLE372)
  • Glenn T. Seaborg Institute
  • National Nuclear Security Administration (89233218CNA000001)

This publication has 33 references indexed in Scilit: